Scancell Holdings plc

Equities

SCLP

GB00B63D3314

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:10 2024-05-23 am EDT			5-day change	1st Jan Change
10.1 ^GBX	0.00%		0.00%	-3.81%

Mar. 26	Scancell doses first patient in melanoma-focused trials	AN
Mar. 22	Seneca Growth Capital announces tepid 2023 results	AN

IN BRIEF: Scancell executive chair and co-founder both to depart

October 26, 2022 at 09:32 am EDT

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Current stock price: 14.86 pence, down 3.4% on Wednesday in London

12-month change: down 31%

By Tom Waite; thomaslwaite@alliancenews.com

Latest news about Scancell Holdings plc

Scancell doses first patient in melanoma-focused trials	Mar. 26	AN
Seneca Growth Capital announces tepid 2023 results	Mar. 22	AN
Scancell Holdings plc Appoints Sath Nirmalananthan to the Board	Mar. 14	CI
Alliance Pharma appoints chair; FireAngel sales down	Feb. 05	AN
Scancell's Chief Development Officer to Step Down	Feb. 05	MT
Scancell Holdings plc Directorate and Executive Changes Changes	Feb. 05	CI
Scancell interim loss narrows amid finance gain on derivative	Jan. 30	AN
Scancell Holdings plc Reports Earnings Results for the Half Year Ended October 31, 2023	Jan. 30	CI
Scancell approved by MHRA to add new cohort to Scope trial	Jan. 17	AN
Scancell Holdings plc Announces Update on SCOPE Trial	Jan. 17	CI
Scancell Raises GBP1.2 Million Via Open Offer	Dec. 19	MT
Scancell raises GBP12 million in total from fundraise	Dec. 19	AN
Scancell Raises GBP11 Million via Share Issue	Dec. 01	MT
Scancell raises GBP10.7 million in upsized share sale	Dec. 01	AN
EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen	Nov. 30	AN
Scancell’s Skin Cancer Vaccine Trial Advances to Second Stage; Shares Up	Nov. 28	MT
Scancell trial progresses; OptiBiotix inks new deal	Nov. 28	AN
Scancell shares up as presents "trailblazing" trial data	Nov. 10	AN
EARNINGS: Frontier IP chair to step down; "busy" Rosslyn narrows loss	23-10-31	AN
Earnings Flash (SCLP.L) SCANCELL HOLDINGS Reports FY23 Revenue GBP5.3M	23-10-31	MT
Scancell Holdings plc Reports Earnings Results for the Full Year Ended April 30, 2023	23-10-31	CI
Scancell says needs more time to publish annual results	23-10-20	AN
Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free	23-09-28	CI
Oxford Technology 2 VCT asset value hurt by AIM share falls	23-09-22	AN
Scancell celebrates "positive" clinical trial data for cancer vaccine	23-09-19	AN

Chart Scancell Holdings plc

Duration

Period

More charts

Company Profile

Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. Its lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-31 - Sachs Oncology Innovation Forum

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.101 GBP

Average target price

0.2467 GBP

Spread / Average Target

+144.23%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SCANCELL HOLDINGS PLC	-3.81%	105M
MODERNA, INC.	+65.24%	62.59B
IQVIA HOLDINGS INC.	-1.34%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.75%	19.09B
BIO-TECHNE CORPORATION	+4.98%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.59%	12.26B
MEDPACE HOLDINGS, INC.	+28.44%	12.05B

Other Biotechnology & Medical Research